AlphaFold predicted structure
NR4A2 · P43354

Mean pLDDT
66.0/ 100
Low
598 residues
Confidence breakdown
- Very high(≥ 90)41%
- Confident(70–90)8%
- Low(50–70)5%
- Very low(< 50)46%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
nuclear receptor subfamily 4 group A member 2
Annotations refreshed 10 hours ago.
Diagnostic Grade (Green)
DDG2P
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownEarly onset or syndromic epilepsy
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownIntellectual disability
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownAdult onset neurodegenerative disorder
BIALLELIC, autosomal or pseudoautosomalAdult onset dystonia, chorea or related movement disorder
BIALLELIC, autosomal or pseudoautosomalParkinson Disease and Complex Parkinsonism
BIALLELIC, autosomal or pseudoautosomalintellectual developmental disorder with language impairment and early-onset DOPA-responsive dystonia-parkinsonism
neurodevelopmental disorder
Parkinson disease
complex neurodevelopmental disorder
late-onset Parkinson disease
Hereditary late-onset Parkinson disease
hereditary disease
autosomal dominant dopa-responsive dystonia
prostatitis
drug allergy
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Nuclear receptor subfamily 4 group A member 2
Transcriptional regulator which is important for the differentiation and maintenance of meso-diencephalic dopaminergic (mdDA) neurons during development (PubMed:15716272, PubMed:17184956). It is crucial for expression of a set of genes such as SLC6A3, SLC18A2, TH and DRD2 which are essential for development of mdDA neurons (By similarity)
NR4A2 · P43354

Mean pLDDT
66.0/ 100
Low
598 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0